The Ebola sweepstakes

Ebola is the NEXT BIG THING that you and your loved ones must fear.

Fear is good!

Fear will stampede millions of consumers into buying any anti-Ebola vaccine they can get their hands on.

At any price!

Here's why it's so important for Ebola to make a beach-head in the rich world. Look what happened to Sovaldi. That's a hep C cure that costs American consumers $84,000. It's available overseas for as little as $300 in its generic versions. When you are a pharmaceutical company peddling cures to terminal illness, you want customers who can pay!

The generics who dole out Sovaldi rip-offs at $300 per treatment are making money, but think of how much more money you can make at $84,000 per!

What's going on right now behind the Ebola scenes is that armies of patent attorneys, intellectual property wizards, and financial wheeler-dealers are jockeying for position to have their Ebola cure be the first to market.

Hundreds of billions of dollars are at stake.

A tiny start-up in Iowa scored the latest media triumph when it was revealed that they held commercial rights to an Ebola vaccine developed in Winnipeg by the Canadian government. NewLink Genetics raised 40 millions in its 2011 IPO. You can find more than that under the couch cushions in the house of Big Pharma.

A little bit of positive media, and NewLink will be a billion dollar concern virtually overnight.

There's big money in Ebola.